Suchergebnisse - "Ding, Yanhua"

PubPharm (189)

1

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of the Anti-IFNAR1 Monoclonal Antibody QX006N : A First-in-Human Single Ascending Dose Study in Healthy Chinese Volunteers

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2024

von Li, X. | Li, B. | Wang, M. | +5

2

Transitioning from NAFLD to MAFLD and MASLD : Consistent prevalence and risk factors in a Chinese cohort

enthalten in: Journal of hepatology | 2024

von Yang, A. | Zhu, X. | Zhang, L. | +1

3

Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection : four randomised clinical trials

enthalten in: The Lancet. Infectious diseases | 2024

von Li, X. | Liu, Y. | Wang, M. | +11

4

The spatial and single-cell analysis reveals remodeled immune microenvironment induced by synthetic oncolytic adenovirus treatment

enthalten in: Cancer letters | 2024

von Liu, G. | Hu, Q. | Peng, S. | +11

5

Phase I study, and dosing regimen selection for a pivotal COVID-19 trial of GST-HG171

enthalten in: Antimicrobial agents and chemotherapy | 2024

von Zhang, H. | Zhou, J. | Chen, H. | +10

6

ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial

enthalten in: Nature communications | 2023

von Hu, Y. | Li, H. | Zhang, H. | +18

7

A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects

enthalten in: Journal of bone oncology | 2023

von Ding, Y. | Liu, Y. | Dou, C. | +1

8

DOSAGE REGIMEN FOR THROMBOPOIETIN RECEPTOR AGONIST

enthalten in: Europäisches Patentamt | 2023

von LIN HONGDA | SHEN KAI | SHEN YAQI | +2

9

DOSAGE REGIMEN FOR THROMBOPOIETIN RECEPTOR AGONIST

enthalten in: Europäisches Patentamt | 2023

von LIN HONGDA | SHEN KAI | SHEN YAQI | +2

10

HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2 : an open-label, dose-escalation, phase 1 trial

enthalten in: Investigational new drugs | 2023

von Zhu, X. | Ding, Y. | Wang, Q. | +3

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[19]